Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide crossover study in adults with type 1 diabetes and overweight or obesity
ACTRN12625000841471Phase 2Not yet recruiting
- Sponsor
- Royal North Shore Hospital
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirzepatide in diabetes mellitus type 1 (T1D), Overweight and obesity (2 arms), sponsored by Royal North Shore Hospital. Primary endpoint: Change in body weight (%). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)Overweightobesity
Beyond the preview
Go deeper on ACTRN12625000841471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000841471.